Last Updated on October 17, 2024 by The Health Master
Zydus Cadila has received tentative approval from the United States US (USFDA) to market Fingolimod capsules in the strength of 0.25 mg (US RLD: Gilenya capsules), the company informed in a statement.
It also said that earlier, in October 2020, the group was granted approval to market Fingolimod capsules in the strength of 0.5mg. It is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).
“The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad,” added the statement.
The group now has 319 approvals and has so far filed over 400 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04, it said.
Alkem gets two observations from USFDA for USA plant
Lupin gets USFDA nod for treatment of Kidney patient
Aleor gets USFDA nod for Testosterone Topical Solution
Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol
Natco gets USFDA nod for Carfilzomib Injection
Lupin gets warning letter from USFDA for Somerset facility
IPC to sensitize stakeholders on manufacturing of Quality Drugs
J Mitra and Company launches C-19 Microlisa Elisa Test kit
Mankind launches drug to treat Diabetes, Heart failure
Dr. Reddy’s Labs launches Icosapent Ethyl Capsules
Cadila Pharma launches Posaconazole to treat fungal diseases
European Commission approves Empagliflozin to treat heart failure
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
